Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20 + lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a populationbased study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0Á002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0Á033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0Á00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0Á027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
Summary
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20 + lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a populationbased study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0Á002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0Á033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0Á00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0Á027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
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Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare B-cell neoplasm that is distinguished from classical Hodgkin lymphoma by morphological and immunological features, including CD20 expression. NLPHL follows a course reminiscent of follicular lymphoma, with wait-and-watch periods, late relapses and a risk of transformation to aggressive lymphoma (Poppema et al, 2008) . In contrast to follicular lymphoma, most patients are young (<50 years), male and present with stage I-IIA disease. The scarcity of this disease has made large clinical trials difficult. In some countries, stage I disease is not treated, especially in children, after the resection of the affected lymph node (Appel et al, 2016) . More common is curative irradiation in early-stage disease (Ann Arbor stage I-IIA), with a relatively high cure rate (Eichenauer et al, 2015) . The prognosis is worse in advanced stages (stage IIB-IV), for which the most common treatment is chemotherapy with or without irradiation. Rituximab has shown promising results, but has not been universally incorporated into standard therapy for advanced NLPHL (Schulz et al, 2008; Advani et al, 2014; Xing et al, 2014) . European Society for Medical Oncology guidelines recommend that NLPHL is treated as classical Hodgkin lymphoma, except stage IA without risk factors (which is treated with 30 Gy local irradiation only) (Eichenauer et al, 2014) . National Comprehensive Cancer Network (NCCN) guidelines also propose local irradiation to nonbulky stage I-IIA and chemotherapy with or without radiation or rituximab to more advanced cases (NCCN, 2014) . Swedish guidelines recommend 30 Gy local irradiation [with or without 2 months of preceding doxorubicin-bleomycinvinblastine-dacarbazine (ABVD)] as standard for stage I-IIA. For stages IIB-IV, our guidelines suggest three options: 6-8 months of ABVD, 6-8 months of rituximab combined with ABVD, or 4 + 4 doses of rituximab monotherapy (http://www.swedishlymphoma.com/hodgkinlymfom).
The aim of this study was to perform the hitherto largest population-based study of NLPHL and to investigate therapeutic changes, particularly in rituximab use.
Materials and methods

Swedish registries
Every clinician and pathologist/cytologist in Sweden is obliged by law to report each occurrence of cancer to the nationwide Swedish Cancer Registry (SCR). The registry includes diagnosis, gender, date of birth, date of diagnosis and the hospital where the diagnosis was made, but no clinical information. The SCR and its diagnostic classification were introduced in 1958. By the 1990s, the SCR was insufficient for the proper registration of most lymphoma entities, so the Swedish Lymphoma Group commissioned the Swedish Lymphoma Registry (SLR), launched nationwide on 1 January 2000 (http://www.swedishlymphoma.com/lymfomreg istret). The purpose of the SLR was to amend the lymphoma registration with information on exact subtype, first-line treatment, localization, stage and other prognostic lymphoma-and patient-specific data. The SLR excludes patients diagnosed at paediatric centres and cases diagnosed at autopsy (http://www.swedishlymphoma.com/lymfomregistre t). When a patient with lymphoma is reported to the SCR, the SLR is notified and sends a form to the attending clinician, requesting additional information. According to yearly reports, the coverage in SLR compared to the mandatory SCR has been 95-97% since its initiation (Junlen et al, 2015) . The SLR has been validated, showing 95% agreement between the diagnosis reported to the SLR and the actual diagnosis in the local patient files (Junlen et al, 2015) . More variables were added to the SLR in 2007. For example, lactate dehydrogenase (LDH) was included at SLR inception, but sedimentation rate (SR) was only introduced in 2007; as a result, LDH was preferred over SR in our analyses. Staging was performed according to the Ann Arbor system (Carbone et al, 1971) : early stage was defined as Ann Arbor stage I-IIA and advanced stage as stage IIB-IV. Bulk was defined as 10 cm or larger in the SLR. For every resident in Sweden, date of death is centrally registered in the Causes of Death Registry, from which survival data was obtained. The population of Sweden is 9Á8 million people. NLPHL was diagnosed according to the World Health Organization criteria (Poppema et al, 2008) , and the specimens were reviewed by an experienced haematopathologist at one of the country's six regional university centres.
Patients
The studied population includes all patients in the SLR newly diagnosed with NLPHL between 1 January 2000 and 31 December 2014, divided into three calendar periods of equal 5-year duration (2000-2004, 2005-2009 and 2010-2014) 
Statistical analysis
The relationship of independent variables with one another was investigated using the v 2 (between categorical variables),
Wilcoxon (between categorical and ordered/continuous variables) and Spearman (between ordered/continuous variables) tests. All patients were observed from date of diagnosis until death, emigration, or end of follow-up (28 February 2015) . Univariate analysis for overall survival was conducted using Kaplan-Meier curves and the log-rank test (Mantel, 1966) . Progression-free or disease-specific survival or transformation rates could not be calculated because the SLR does not contain that information. Factors significant in univariate analysis competed in multivariate analysis, using forward stepwise Cox regression; the proportional hazards assumption was checked with graphs based on Schoenfeld residuals (Cox, 1972) . All P values are two-tailed and calculated using Stata 9.2 (StataCorp, College Station, TX, USA). P < 0Á05 was considered significant.
Results
Two out of 160 patients diagnosed with NLPHL in the studied period were diagnosed with a concomitant transformation to diffuse large B-cell lymphoma (DLBCL) and excluded from further analyses. The median age was 48 years; the oldest patient was 88 years (Table I ). The incidence did not increase over time (64, 41 and 53 patients were diagnosed 2000-2004, 2005-2009 and 2010-2014, respectively) . During 2000-2014, staging with positron emission tomography-computed tomography became increasingly common (and a nationwide standard in 2010), however, the later calendar periods did not include significantly more advanced stages (P = 0Á28). Nor did other clinical characteristics vary over time (data not shown). Bulky disease was seen in eight patients (three in stage IIA, one in stage III, four in stage IV). Ann Arbor stages among patients with advanced stage disease were IIB (n = 8), IIIA (n = 24), IIIB (n = 2), IVA (n = 7) and IVB (n = 8).
Treatment
Information on first-line therapy existed in 142/158 patients (90%), and there were no differences in survival (P = 0Á95) nor in prognostic factors compared with the 16 patients without treatment data. The median time from diagnosis to start of therapy was 49 days (range, 0-173 days). First-line regimens are presented in Table II . The 22 patients reported (using an old variant of the report form) as D. Molin et al only having received 'therapy with curative intent' (including either or both of chemotherapy and radiotherapy, but not rituximab) had similar survival compared with other patients (P = 0Á41). As the patients not given therapy (except surgery) were few (n = 6) and much older (median 70Á5 years), the impact of this approach on outcome was not further analysed (2/6 had died by the time of this analysis).
With each calendar period (2000-2004, 2005-2009, 2010-2014) , rituximab as part of primary therapy became gradually more common (Table III) . Otherwise, there were no therapeutic differences over time (data not shown).
Survival analysis
Median follow-up time in surviving patients was 7Á3 years (range, 0Á6-15Á0). The median follow-up times in patients diagnosed in the three calendar periods were 12Á4, 7Á4 and 3Á2 years, respectively. Overall survival of all 158 patients is shown in Fig 1A ; 5-year overall survival was 94% [95% confidence interval (CI), 89-97%] and 10-year overall survival 79% (95% CI, 69-86%). Several clinical factors predicted inferior survival (Table I) , including age, advancedstage disease and female gender (Fig 1B-D) . In total, there were 21 deaths (13%). Among patients ≤50 years, there were 5 deaths (6%). No patient treated with rituximab died (Fig 2) .
Because therapy was dependent on disease stage, which in itself affected outcome, further analyses of therapy and survival were performed separately for stages I-IIA and IIB-IV. Treatment and survival in stage I-IIA Survival among the 109 patients with early-stage-disease was excellent (Fig 1B) , with a 5-and 10-year overall survival of 98% (95% CI, 91-99%) and 85% (95 CI, 7-92%), respectively. The 5-and 10-year overall survival for patients aged ≤60 years was 100% and 93% (95% CI, 80-97%), respectively. Local radiotherapy (with or without chemotherapy) had been given to 73%, chemotherapy only to 10%, and rituximab (with or without chemotherapy) to 17%. There were no significant overall survival differences between these first-line approaches (P = 0Á80). There were also no significant survival differences between radiotherapy alone or radiotherapy combined with chemotherapy (P = 0Á18; 10-year survival 75% vs. 92%; median age 50 vs. 39Á5 years). The 13 patients 'treated with curative intent' had the same overall survival as others (P = 0Á49). In early stage diseases, there was no significant survival difference between calendar periods (P = 0Á20).
Treatment and survival in stage IIB-IV
Five-and 10-year overall survival among the 49 patients with advanced-stage disease was 87% (95% CI, 73-94%) and 64% (95% CI, 42-79%). For patients aged ≤60 years, 5-and 10-year survival was 96% (95% CI, 77-99%) and 78% (95% CI, 51-92%). Therapy without rituximab had been given to 55% and 45% received rituximab-containing regimens. There was a significant difference in overall survival between these two groups, with 5-and 10-year OS at 100% for rituximab-treated patients, compared with 5-and 10-year OS at 78% and 55% for those who did not receive rituximab (P = 0Á033; Fig 2B) . Also significant for overall survival were age (P = 0Á013), gender (P = 0Á008) and bulky disease (P = 0Á0003). Because there was no mortality in the rituximab group, a subsequent Cox analysis could not be conducted. However, there were no differences in the distribution of prognostic variables between patients treated with and without rituximab (Table III) .
Differences between female and male patients
Female patients showed inferior overall survival in univariate analysis (Table I ; Fig 1C) . However, there was another large difference between women and men: the median age of the female patients was 15 years older than that of male patients (59 vs. 44 years; P = 0Á002). Overall, 26% of the patients were female and accounted for 13% and 59% of patients aged ≤30 and >70 years, respectively. The distributions of ages in the sexes are shown in Fig 3: men present a bi-modal age distribution that is not apparent in women. No other clinical factor differed between the sexes (P ≥ 0Á4 for every comparison). In multivariate analysis, with respect to overall survival, age (P = 0Á002), bulky disease (P = 0Á003) and disease stage (P = 0Á007), but not gender, were independent. There were no gender differences in rituximab use (Table III) .
Differences between calendar periods
As described above, first-line rituximab use increased with each calendar period, particularly in patients with advanced stages (Table III) . In advanced stage patients, overall survival improved with each calendar period (P = 0Á035; Fig 2C) . Because the follow-up time naturally was short for patients diagnosed in the most recent calendar period, the above analysis was repeated in a comparison between 2000-2004 (7% first-line rituximab) and 2005-2014 (67% first-line rituximab), again showing improved survival (multivariate P = 0Á027, adjusted for sex, age and bulky disease); 5-and 10-year overall survival for 2000-2004 was 71% (95% CI, 43-87%) and 53% (95% CI, 28-73%), but for 2005-2014 it was 96% (95% CI, 73-99%) and 72% (95% CI, 31-91%). In advanced patients not given upfront rituximab, there were no survival differences between calendar periods (P = 0Á49).
Discussion
This is, to our knowledge, the hitherto largest populationbased study of NLPHL. All patients diagnosed in Sweden during a 15-year period (between 2000 and 2014) have been included. This is also the first population-based study to investigate the clinical impact of rituximab in NLPHL. The male predominance (74%) agrees with previous studies, in which the range was reported as 66-88% (Bodis et al, 1997; Diehl et al, 1999; Feugier et al, 2004; Wirth et al, 2005; Chera et al, 2007; Nogova et al, 2008; Al-Mansour et al, 2010; Biasoli et al, 2010; Chen et al, 2010; Jackson et al, 2010; Farrell et al, 2011; Savage et al, 2011; Eichenauer et al, 2015; Kenderian et al, 2016; Strobbe et al, 2016) . Our fraction of early-stage cases (69%) is similar to the other three population-based studies: 67% (Al-Mansour et al, 2010), 75% (Farrell et al, 2011) and 81% (Strobbe et al, 2016) . In the present analysis, the median age was 48 years, which is higher than in those reported by Al-Mansour et al (2010), Farrell et al (2011) and Strobbe et al (2016) (37, 39 and 43 years, respectively) . This is explained by the design of the SLR, which does not include cases diagnosed at paediatric centres, and by our old source population: Swedes with NLPHL had a median age of 40Á8 years in 2010 (http://www. statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__ BE0101B/BefolkMedianAlder/table/tableViewLayout1/?rxid= 0f398921-9799-410f-bff6-eeb16b5ecbae). Patients with earlystage disease showed a 10-year overall survival of 85% (93% for those aged ≤60 years), while 10-year overall survival in those with advanced stages was 64% (78% in those aged ≤60 years).
In analyses of the therapy used, we found that no patient treated upfront with rituximab (with or without chemotherapy) had died. In the 109 patients with early-stage NLPHL, there were only nine deceased patients [who were much older (P = 0Á001) with a median age of 67 years at diagnosis (range, 36-84)], and there were no survival differences between therapies. In the 49 patients with advanced stages, there were 12 deaths [these deceased patients were also older at diagnosis (median age, 64 years; range, 18-78); P = 0Á040]. None of the 21 patients who died had received rituximab upfront. Patients treated with rituximab were the same age as those who were not (median, 51 vs. 52 years; Table III ). The absence of deaths in the rituximab-treated patients prohibited Cox analysis, which requires at least one death in each group for hazard ratio calculation. However, there were no imbalances in the distributions of prognostic factors between those treated with rituximab and those who were not (Table III) . We also saw an increasing use of rituximab in the later calendar periods (P < 0Á00005), and survival was better in the later calendar periods (P = 0Á027).
Although all patients were diagnosed in this millennium and treated under the modern paradigm, patients still have a long follow-up [median, 7 years (5 years for rituximab-treated patients)], which makes this population-based cohort not only the largest but also the one with the longest follow-up time (Al-Mansour et al, 2010; Farrell et al, 2011; Strobbe et al, 2016) . In advanced stages, the survival rate for patients not treated with rituximab appears inferior compared with other series (Nogova et al, 2008; Xing et al, 2014) . We explain this by the older patient population and the realworld, nationwide character of our material (whereas the other series are from trial databases or single centres/regions). Our study includes all Swedish patients treated at all kinds of centres. Our guidelines are similar to those of the NCCN. However, survival improved markedly over time. We have here offered increasing first-line use of rituximab as the most likely explanation, but it reasonable to assume that there has also been a simultaneous increase in the use of rituximab for relapse therapy, which would mean that patients diagnosed in one calendar period would receive relapse rituximab-containing therapy according to the standards of a later time. However, that effect would only dilute the large differences between the calendar periods, and it would not lead to false conclusions about the importance of rituximab. Still, it is safe to say that the increasing use of rituximab (whether in primary or later treatments) appears to be associated with better survival. An identical phenomenon of increased rituximab use and improved overall survival over time has also been reported for follicular lymphoma in Sweden (Junlen et al, 2015) .
The limitations of our study should be noted. Although it is the largest population-based study of NLPHL, it consists of 158 patients (after the exclusion of two patients with contemporaneous DLBCL), and the low death rate makes firm conclusions about survival difficult. Furthermore, the registry only has information on first-line therapy and survival, but not on subsequent therapies, relapses or transformation rates, nor is a central pathology review possible (however, the rare NLPHL is never diagnosed without a second review at one of the country's six regional university centres by an experienced haematopathologist). No patients have been lost to follow-up; therefore, the survival analysis is entirely unbiased. This study also provides externally valid data from all patients with NLPHL in a Scandinavian country. This unselected, population-based cohort allows for an estimation of the distributions and prevalence rates of relevant variables and we found a large age difference between women and men. This has, to our knowledge, not been reported before, and it is therefore a novel finding. In the present study of 41 women and 117 men, the median female patient's age was 59 years compared with 44 years for males (P = 0Á002). This is a rare disease, particularly in women. Thus, the low numbers of women included in previous population-based reports [N = 26 (Al-Mansour et al, 2010) , N = 21 (Farrell et al, 2011) and N = 11 (Strobbe et al, 2016) ] could have hindered a statistically significant detection of age differences. Unadjusted, female sex appeared to predict poor overall survival, but when adjusted for age and other factors, it was irrelevant for prognosis.
Rituximab has shown promising results, but there appear to be frequent and late relapses after therapy, and concerns have been raised about more transformations after rituximab monotherapy (Schulz et al, 2008; Eichenauer et al, 2011; Advani et al, 2014) . The absence of mortality in our Swedish patients treated with rituximab could suggest that the drug does not cause excessive numbers of transformation to aggressive lymphoma. However, a very large, long-term single-centre study from the Mayo Clinic recently showed no inferior survival in the 7Á6% of patients who had transformation to DLBCL (transformation rate of 0Á74 per 100 patient-years) (Kenderian et al, 2016) . Avoidance of late toxicities and consideration of therapy against a future transformed lymphoma must be taken into account in this indolent disease. Many patients die from secondary tumours (Diehl et al, 1999) and transformations to aggressive lymphoma have been reported to occur in 3% (Farrell et al, 2011) , 8% (Strobbe et al, 2016) and 13% (Al-Mansour et al, 2010) of population-based reports. In the present cohort there were concomitant transformations to DLBCL in 2/160 patients (1%) at the time of the NLPHL diagnosis.
In Sweden, new NLPHL guidelines are currently under development: these will include rituximab as part of first-line therapy for all patients with NLPHL. It might be argued that future trials should be designed to investigate whether anthracyclines could be avoided in primary therapy and retained for future transformation therapy, similar to the management of other indolent B-cell lymphomas.
We conclude that there is a 15-year age difference between women and men in NLPHL. The cause of this difference is not known. Furthermore, the prognosis of NLPHL has improved in advanced-stage disease concurrently with increasing rituximab use, and there is no mortality in Swedish patients treated with rituximab as primary therapy.
